New production lapses found at Eli Lilly plant, Reuters reports

The FDA recently found new manufacturing problems at an Eli Lilly’s plant in Branchburg, New Jersey, Reuters reports. According to government records obtained by Reuters, the FDA’s inspection found eight separate deficiencies, including problems in tracking manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment. Lilly said in a statement to Reuters that the inspection followed a company request to the FDA to make a change to its manufacture of migraine treatment Emgality.